Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305397 | 0.82 | — | — | |
| SCHEMBL17423456 | 0.80 | PIK3CD (0.33) | PIK3CDHTTKMT2ASMN1; SMN2TDP1 | |
| SCHEMBL305004 | 0.77 | — | — | |
| SCHEMBL304922 | 0.77 | — | — | |
| SCHEMBL10318403 | 0.76 | PIK3CD (0.32) | PIK3CDHTTKMT2ASMN1; SMN2TDP1 | |
| SCHEMBL17895344 | 0.76 | PIK3CD (0.32) | PIK3CDHTTKMT2ASMN1; SMN2TDP1 | |
| SCHEMBL74560 | 0.76 | TP53 (0.47) | SMN1; SMN2 | |
| SCHEMBL1497934 | 0.76 | ADRB2 (0.33) | PIK3CD | |
| SCHEMBL28679506 | 0.76 | MIF (0.30) | — | |
| SCHEMBL72482 | 0.75 | CES2 (0.50) | HTTKMT2ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2024-06-20 | — | — | US | disclosed |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4384226-A2 | DIPHOSPHINE COMPOUNDS AND COMPLEXES | Cancer Research Technology Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-4370114-A2 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Mydecine Innovations Group Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158443-A1 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | UNIV COLORADO REGENTS (US) | 2024-05-16 | — | — | US | disclosed |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-03-28 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003037321-A1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| US-20030008896-A1 | Isoquinolinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-01-09 | — | — | US | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | PIK3CD 556/4885HTT 2725/4885KMT2A 1372/4885 |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | PIK3CD 3853/4885HTT 128/4885KMT2A 287/4885 |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | PIK3CD 843/4885HTT 2465/4885KMT2A 1078/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | PIK3CD 4106/4885HTT 687/4885KMT2A 589/4885 |
| US-20240158443-A1 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | VIP, PTMS, QPCT | PIK3CD 2622/4885HTT 1740/4885KMT2A 3377/4885 |
| US-20030008896-A1 | Isoquinolinone derivatives | PARP1, PARP2, PARP3 | PIK3CD 1419/4885HTT 642/4885KMT2A 1847/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | PIK3CD 4450/4885HTT 620/4885KMT2A 2579/4885 |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | PIK3CD 843/4885HTT 2465/4885KMT2A 1078/4885 |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | PIK3CD 843/4885HTT 2465/4885KMT2A 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.